CIMT 2018：推动癌症免疫治疗的前沿进展——第十六届癌症免疫治疗协会年会报告。
CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16 Annual Meeting of the Association for Cancer Immunotherapy.
机构信息
a TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH , Mainz , Germany.
出版信息
Hum Vaccin Immunother. 2018;14(12):2864-2873. doi: 10.1080/21645515.2018.1504526. Epub 2018 Aug 29.
Abstract
The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's largest meeting series of its kind, took place in Mainz, Germany from 15-17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto "Pushing Frontiers in Cancer Immunotherapy". This meeting report is a summary of some of the CIMT 2018 highlights.
摘要
第十六届癌症免疫治疗协会（CIMT）年会在德国美因茨举行，该会议是欧洲同类会议中规模最大的会议系列，于 2018 年 5 月 15 日至 17 日举行。会议以“推动癌症免疫治疗的前沿”为主题，探讨了癌症免疫治疗方面的最新进展。本会议报告总结了 2018 年 CIMT 的部分亮点。
相似文献
1
CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16 Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2018：推动癌症免疫治疗的前沿进展——第十六届癌症免疫治疗协会年会报告。
Hum Vaccin Immunother. 2018;14(12):2864-2873. doi: 10.1080/21645515.2018.1504526. Epub 2018 Aug 29.
2
CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2021：癌症免疫治疗协会第十八届年会报告。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2024416. doi: 10.1080/21645515.2021.2024416. Epub 2022 Feb 7.
3
CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2022：癌症免疫治疗协会第十九届年会报告。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2124785. doi: 10.1080/21645515.2022.2124785. Epub 2022 Oct 12.
4
CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.2016年癌症免疫治疗国际会议：癌症免疫治疗疗效机制——2016年5月10 - 12日于德国美因茨举行的癌症免疫治疗协会第14届年会报告
Hum Vaccin Immunother. 2016 Nov;12(11):2805-2812. doi: 10.1080/21645515.2016.1206677. Epub 2016 Jul 19.
5
CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2024：癌症免疫治疗协会第 21 届年会报告。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2381925. doi: 10.1080/21645515.2024.2381925. Epub 2024 Jul 23.
6
CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy.2019年国际分子靶向治疗和癌症免疫治疗大会：癌症免疫治疗协会第17届年会报告
Hum Vaccin Immunother. 2020 Apr 2;16(4):808-815. doi: 10.1080/21645515.2019.1675459. Epub 2019 Nov 11.
7
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.2014年癌症免疫治疗进展：癌症免疫治疗协会第12届年会报告——2014年5月6 - 8日于德国美因茨召开
Hum Vaccin Immunother. 2014;10(10):3090-100. doi: 10.4161/hv.29767.
8
CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.2013年癌症免疫治疗学会年会：推进靶向治疗——2013年5月14 - 16日于德国美因茨召开的第11届癌症免疫治疗学会年会报告
Hum Vaccin Immunother. 2013 Sep;9(9):2025-32. doi: 10.4161/hv.25768. Epub 2013 Jul 22.
9
CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.2017年国际肿瘤免疫治疗学会年会：周年研讨会——第15届国际肿瘤免疫治疗学会年会报告
Hum Vaccin Immunother. 2017 Oct 3;13(10):2272-2279. doi: 10.1080/21645515.2017.1358327.
10
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.第 25 届国际癌症生物治疗学会年会综述。
J Transl Med. 2011 May 12;9:60. doi: 10.1186/1479-5876-9-60.
本文引用的文献
1
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 T Cells in Synovial Sarcoma.过继转移 NY-ESO-1 细胞在滑膜肉瘤中与抗肿瘤活性相关联，且具有持久的存在。
Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.
2
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.慢性淋巴细胞白血病中 CD19 嵌合抗原受体 (CAR) T 细胞治疗应答和耐药的决定因素。
Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.
3
Personalized vaccines for cancer immunotherapy.用于癌症免疫治疗的个体化疫苗。
Science. 2018 Mar 23;359(6382):1355-1360. doi: 10.1126/science.aar7112.
4
Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry.使用非天然组合化学的流感疫苗肽模拟物。
J Clin Invest. 2018 Apr 2;128(4):1569-1580. doi: 10.1172/JCI91512. Epub 2018 Mar 12.
5
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.癌症疫苗配方决定了与 CTLA-4 和 PD-L1 检查点阻断疗法的协同作用。
J Clin Invest. 2018 Apr 2;128(4):1338-1354. doi: 10.1172/JCI93303. Epub 2018 Feb 26.
6
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.TGFβ 通过促使 T 细胞排除而减弱肿瘤对 PD-L1 阻断的反应。
Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.
7
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.自然杀伤细胞刺激 cDC1 细胞向肿瘤微环境募集，促进癌症免疫控制。
Cell. 2018 Feb 22;172(5):1022-1037.e14. doi: 10.1016/j.cell.2018.01.004. Epub 2018 Feb 8.
8
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
9
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
10
The renaissance of complement therapeutics.补体疗法的复兴。
Nat Rev Nephrol. 2018 Jan;14(1):26-47. doi: 10.1038/nrneph.2017.156. Epub 2017 Dec 4.
Zotero 插件